Telitacicept plus baricitinib for hard-to-treat rheumatoid arthritis
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study tests a combination of two drugs (telitacicept and baricitinib) for people with stubborn rheumatoid arthritis that hasn't improved with other treatments. The goal is to see if this combination is safe and effective in reducing joint pain and inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- You have rheumatoid arthritis that is refractory (hasn't gotten better with at least two different types of advanced drugs).
- You are willing to take a combination of two medicines: telitacicept and baricitinib.
- You do not have severe heart, liver, or lung disease, active cancer, or another autoimmune disease.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
- You have no known allergies to telitacicept or baricitinib.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining Telitacicept and Tofacitinib can help people with rheumatoid arthritis that hasn't improved with at least two other advanced treatments. The goal is to see if these drugs work better together for hard-to-treat cases.
This trial tests if a new medication, telitacicept, is safe and effective for people with difficult-to-treat rheumatoid arthritis. It may be an option for patients who have not found relief from other treatments.
This study tests whether combining two medicines—methotrexate and tofacitinib—works better for people with a specific type of rheumatoid arthritis. It may be a good fit if you have moderate to severe arthritis, have had a joint biopsy that shows a certain cell pattern, and haven't used similar treatments before.
This trial studies advanced medicines for rheumatoid arthritis (RA) in people whose RA is still active despite several standard treatments. It may help by testing whether a different advanced option can better control symptoms and joint inflammation.
This trial studies an add-on treatment approach for rheumatoid arthritis (RA) in adults whose symptoms did not improve with standard “first-line” medicines. It may help people who still have active RA after trying certain disease-modifying drugs.
This trial tests a step-by-step plan for treating rheumatoid arthritis when current medicines aren’t controlling the disease. It compares how well a targeted approach works by adjusting treatment for people who need a TNF inhibitor.
Hear when a new Telitacicept trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.